This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Sponsored Interviews

Tools4Patient aims to reduce effect of placebo response in clinical trials

Posted by on 06 January 2019
Share this article

Tools4Patient was founded by a group of industry veterans of clinical trials to accelerate the launch of drugs to patients by developing predictive algorithms to focus on the detrimental placebo response that has plagued clinical trial analysis for many years. The result has been a product called Placebell, which uses a sophisticated date-driven approach to minimize the placebo effect. Erika Smith, VP of Business Development, explains that Placebell is calibrated to specific diseases depending on the clinical trial, has completed several trials, and is being expanded to work in more indications all the time. Further, Placebell significantly increases the likelihood that the clinical trial will identify a true therapeutic effect.

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down